Skip to main navigation

Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

09.6.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

09.5.23

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

08.8.23

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

08.8.23

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

08.3.23

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

08.3.23

Terns Pharmaceuticals Announces Leadership Transition

07.18.23

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

07.5.23

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

06.26.23

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

06.6.23

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2023 Terns Pharmaceuticals, Inc. Privacy Policy